Risperidone: a review of efficacy studies in adolescents with schizophrenia.
Risperidone has been approved by the Food and Drug Administration for the treatment of schizophrenia in the adolescent population. This new indication has been a result of data obtained from two pivotal double-blind trials with supplemental information from open-label and retrospective trials. This brief article provides an overview of risperidone's pharmacological profile followed by information on the double-blind trials that have resulted in the approval of risperidone for the treatment of adolescent schizophrenia.
Madaan
Vishal
V
Department of Psychiatry, Creighton University/University of Nebraska Medical Center, Omaha, Nebraska 68131, USA. vishalmadaan@creighton.edu
D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D018967:Risperidone / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D018967:Risperidone